Literature DB >> 22206641

N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis.

Jessica R Terrill1, Hannah G Radley-Crabb, Miranda D Grounds, Peter G Arthur.   

Abstract

Oxidative stress is implicated as a factor that increases necrosis of skeletal muscles in Duchenne Muscular Dystrophy (DMD) and the dystrophic mdx mouse. Consequently, drugs that minimize oxidative stress are potential treatments for muscular dystrophy. This study examined the in vivo benefits to mdx mice of an antioxidant treatment with the cysteine precursor N-acetylcysteine (NAC), administered in drinking water. NAC was completely effective in preventing treadmill exercise-induced myofibre necrosis (assessed histologically) and the increased blood creatine kinase levels (a measure of sarcolemma leakiness) following exercise were significantly lower in the NAC treated mice. While NAC had no effect on malondialdehyde level or protein carbonylation (two indicators of irreversible oxidative damage), treatment with NAC for one week significantly decreased the oxidation of glutathione and protein thiols, and enhanced muscle protein thiol content. These data provide in vivo evidence for protective benefits of NAC treatment on dystropathology, potentially via protein thiol modifications.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206641     DOI: 10.1016/j.nmd.2011.11.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  27 in total

1.  Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.

Authors:  Luis Henrique Rapucci Moraes; Roberta Constâncio Bollineli; Daniela Sayuri Mizobuti; Leonardo Dos Reis Silveira; Maria Julia Marques; Elaine Minatel
Journal:  Redox Rep       Date:  2014-10-31       Impact factor: 4.412

2.  Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.

Authors:  Jessica R Terrill; Gavin J Pinniger; Jamie A Graves; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2016-01-18       Impact factor: 5.182

3.  Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy.

Authors:  Anna Cho; May Christine; V Malicdan; Miho Miyakawa; Ikuya Nonaka; Ichizo Nishino; Satoru Noguchi
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150

4.  Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Authors:  Liubov V Gushchina; Sayak Bhattacharya; Kevin E McElhanon; Jin Hyuk Choi; Heather Manring; Eric X Beck; Jenna Alloush; Noah Weisleder
Journal:  Mol Ther       Date:  2017-07-03       Impact factor: 11.454

5.  Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat.

Authors:  Stewart I Head
Journal:  J Physiol       Date:  2017-10-29       Impact factor: 5.182

6.  Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Gavin J Pinniger; Jessica R Terrill; Evanna B Assan; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2017-09-30       Impact factor: 5.182

7.  Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice.

Authors:  Ken'ichiro Nogami; Yusuke Maruyama; Fusako Sakai-Takemura; Norio Motohashi; Ahmed Elhussieny; Michihiro Imamura; Satoshi Miyashita; Megumu Ogawa; Satoru Noguchi; Yuki Tamura; Jun-Ichi Kira; Yoshitsugu Aoki; Shin'ichi Takeda; Yuko Miyagoe-Suzuki
Journal:  Hum Mol Genet       Date:  2021-05-31       Impact factor: 6.150

Review 8.  Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview.

Authors:  Annamaria De Luca
Journal:  Acta Myol       Date:  2012-05

9.  Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Authors:  Janelle M Spinazzola; Louis M Kunkel
Journal:  Expert Opin Orphan Drugs       Date:  2016-10-18       Impact factor: 0.694

10.  Sarcospan: a small protein with large potential for Duchenne muscular dystrophy.

Authors:  Jamie L Marshall; Rachelle H Crosbie-Watson
Journal:  Skelet Muscle       Date:  2013-01-03       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.